Radiation Nephritis

Luxton, R.W.; Kunkler, P. B.

doi:10.3109/02841866409134143

Cited by 58 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic radiation-induced nephropathy consists of vascular damage in combination with progressive loss of parenchymal cells. This may follow the acute syndrome or present years after irradiation [48][49][50][51]. To reduce the risk of renal toxicity after administration of [177Lu]Lu-SSRT, protocols for renal protection have been developed involving co-infusion of amino acids that compete for the megalin receptor on tubular cells.…”

Section: Kidneys and Livermentioning

confidence: 99%

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Gleisner

Chouin

Gabiña

et al. 2022

Eur J Nucl Med Mol Imaging

107

View full text Add to dashboard Cite

The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.

show abstract

Section: Kidneys and Livermentioning

confidence: 99%

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Gleisner

Chouin

Gabiña

et al. 2022

Eur J Nucl Med Mol Imaging

107

View full text Add to dashboard Cite

show abstract

“…The clinico‐pathological findings and timing of onset are compatible with radiation nephritis (Bergstein et al , 1986; Guinan et al , 1988; Tarbell et al , 1988; Antignac et al , 1989; Lonnerholm et al , 1991; Cohen et al , 1993, 1995). This is thought to be stimulated by injury to the vascular endothelium and typically presents 6–12 months after BMT (Luxton & Kunkler, 1964; Keane et al , 1976; Krochak & Baker, 1986), the latent period being attributed to slow endothelial turnover and progressive tissue damage (Krochak & Baker, 1986; Baker & Krochak, 1989).…”

Section: Renalmentioning

confidence: 99%

“…The tolerance of renal tissue to radiation damage lies in the region of 20–25 Gy of radiation delivered to both kidneys, which are higher doses than those used in paediatric BMT (Luxton & Kunkler, 1964; Keane et al , 1976; Lawton et al , 1991). The patients reported by Guinan et al (1988) and Tarbell et al (1988) had all received multiagent conditioning chemotherapy, in addition to radiation, particularly those with neuroblastoma who had received the nephrotoxic radiation sensitizer cis ‐platinum.…”

Section: Renalmentioning

confidence: 99%

Non‐endocrine late complications of bone marrow transplantation in childhood: part I

Leiper¹

2002

Br J Haematol

View full text Add to dashboard Cite

“…Luxton identified radiation nephropathy as occurring acutely, within one year, or chronically, at up to five years after irradiation (16). It is possible that longer follow-up may yield additional cases.…”

Section: Discussionmentioning

confidence: 99%

Mitigation of Late Renal and Pulmonary Injury After Hematopoietic Stem Cell Transplantation

Cohen

Bedi

Irving

et al. 2012

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose To update the results of a clinical trial that assessed whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure and pulmonary-related mortality in subjects undergoing total body irradiation (TBI) in preparation for hematopoietic stem cell transplantation (HSCT). Methods and Materials Updated records of the 55 subjects who were enrolled in this randomized controlled trial were analyzed. There were 28 on captopril and 27 on placebo. The definitions of TBI-HSCT-related chronic renal failure (and relapse) were the same as in the 2007 analysis. Pulmonary-related mortality was based on clinical or autopsy findings of pulmonary failure or infection as the primary cause of death. Follow-up data for overall and pulmonary-related mortality was supplemented by use of the National Death Index. Results The risk of TBI-HSCT-related chronic renal failure was lower in the captopril group (11% at 4 years) than in the placebo group (17% at 4 years) but this was not statistically significant (p>0.2). Analysis of mortality was greatly extended by use of the National Death Index, and no patients were lost to follow-up for reasons other than death prior to 67 months. Patient survival was higher in the captopril compared with the placebo group, but this was not statistically significant (p>0.2). The improvement in survival was influenced more by a decrease in pulmonary mortality (11% risk at 4 years in the captopril group vs. 26% in the placebo group, p=0.15) than by the decrease in chronic renal failure. There was no adverse effect on relapse risk (p=0.4). Conclusions Captopril therapy produces no detectable adverse effects when given after TBI. Captopril therapy reduces overall and pulmonary-related mortality after radiation-based HSCT and there is a trend towards mitigation of chronic renal failure.

show abstract

Radiation Nephritis

Cited by 58 publications

References 5 publications

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Non‐endocrine late complications of bone marrow transplantation in childhood: part I

Mitigation of Late Renal and Pulmonary Injury After Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About